Protagenic Therapeutics (PTIX) Stock Price, News & Analysis

Company Overview

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Key Stats

• Today's Range: $0.26 to $0.27
• 50-Day Range: $0.25 to $0.66
• 52-Week Range: $0.25 to $1.87
• Volume: 64,533 shs
• Average Volume: 596,430 shs
• Market Capitalization: $1.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTIX Stock Analysis - Frequently Asked Questions

How have PTIX shares performed this year?

Protagenic Therapeutics' stock was trading at $0.49 at the beginning of the year. Since then, PTIX stock has decreased by 45.8% and is now trading at $0.2655.
View the best growth stocks for 2025 here.

How were Protagenic Therapeutics' earnings last quarter?

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) posted its earnings results on Tuesday, November, 16th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03.

How do I buy shares of Protagenic Therapeutics?

Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Protagenic Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protagenic Therapeutics investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), NVIDIA (NVDA), Cytokinetics (CYTK), Processa Pharmaceuticals (PCSA), Acasti Pharma (ACST) and Akero Therapeutics (AKRO).

Company Calendar

• Last Earnings: 11/16/2021
• Today: 2/22/2025
• Next Earnings (Estimated): 3/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTIX
• CUSIP: N/A
• CIK: 1022899
• Web: www.protagenic.com
• Phone: 212-994-8200
• Fax: 603-761-6223
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,000,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -308.97%
• Return on Assets: -228.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.80
• Quick Ratio: 1.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.83 per share
• Price / Book: 0.32

Miscellaneous

• Outstanding Shares: 7,240,000
• Free Float: 4,707,000
• Market Cap: $1.92 million
• Optionable: Not Optionable
• Beta: 0.25